Cuba seeks to produce millions of vaccine candidate doses
Cuba seeks to produce millions of vaccine candidate doses
Havana, Feb 22 (Prensa Latina) Cuba s Biopharmaceutical Industry is presently beavering away to achieve a productive escalation of millions of Sovereign 02 vaccine candidate doses, the most advanced against Covid-19, as reported by the local press.
Roselyn Martínez, deputy director of Industrial Operations of the Finlay Vaccine Institute, also reiterated that hundreds of thousands of Cuban candidate have already been produced so as to begin its phase III of clinical trials in March.
Soberana 02 vaccine candidate is produced on a large scale at the Biocen parenteral plant, belonging to the BioCubaFarma Business Group, a leader in Cuban biotechnology.
Cuba´s Soberana 02 vaccine candidate is a world trend
Cuba´s Soberana 02 vaccine candidate is a world trend
Havana, Feb 22 (Prensa Latina) Within a few days of starting phase III of clinical trials with 42,600 volunteers, Soberana 02 vaccine has been latest news domestically and internationally. Hopeful vaccine , safe technology , the first vaccine candidate in Latin America and extraordinary breakthrough are just some phrases on several articles on The New York Times, Business Insider, EuroNews and the BBC.
Soberana 02 is a global trending because it is innovative. It is the only candidate for the conjugate vaccine platform in the world . Soon . another start, Dagmar García, research director of the Finlay Vaccine Institute, tweeted.